Vanda v. Teva: Circadian Rhythm Patent Case Transferred to Delaware in 45 Days
Vanda Pharmaceuticals filed suit in the District of New Jersey against Teva over US11285129B2, a patent covering treatment of circadian rhythm disorders. The court granted defendants' cross-motions to transfer to the District of Delaware just 45 days after filing — before any merits ruling.
Venue battle resolves in 45 days: New Jersey to Delaware
On December 27, 2022, Vanda Pharmaceuticals, Inc. filed a patent infringement action in the U.S. District Court for the District of New Jersey against Teva Pharmaceutical Industries, Ltd. The asserted patent — US11285129B2 (application no. US17/368160) — covers treatment of circadian rhythm disorders. The case is one of a pair of related actions filed simultaneously (the companion being Case No. 22-7529, involving Apotex Inc. and Apotex Corp.).
The recorded basis of termination is Case Transferred. On February 10, 2023, the court granted defendants' cross-motions to transfer both related actions to the District of Delaware pursuant to 28 U.S.C. § 1404. The docket order states that the court considered the parties' submissions, including declarations, exhibits, and full briefing, before granting the transfer. No merits ruling on infringement or validity was issued in New Jersey.
The transfer was resolved in just 45 days from filing — before substantive litigation began — suggesting the defendants mounted an early and well-supported venue challenge. Why New Jersey was found to be a less appropriate forum than Delaware, and what specific factors drove the § 1404 analysis, are detailed in the accompanying opinion referenced in the order; the ultimate merits of the infringement claims remain to be litigated in Delaware.
See Complete Case & Patent Analysis →Filing to Case Transferred in 45 days
45 days from filing to transfer order — an unusually swift venue resolution
US11285129B2 — Treatment of Circadian Rhythm Disorders
Any company developing or commercialising treatments for circadian rhythm disorders — including sleep-wake cycle therapies, chronobiotic agents, or related formulations — should assess freedom-to-operate against US11285129B2. The active Delaware litigation means Vanda is actively enforcing this patent, and the scope of its claims should be reviewed before any product launch or ANDA filing in this therapeutic category.
Official order — verbatim text
The court's transfer order granted defendants' cross-motions under 28 U.S.C. § 1404 after reviewing full briefing, declarations, and exhibits. The order makes no ruling on infringement or validity — it resolves only the question of the more appropriate forum. Both related actions (22-7528 and 22-7529) were transferred to the District of Delaware simultaneously, consolidating the venue question across both defendant groups.
No dismissal — the case continues in a new venue
A transfer under 28 U.S.C. § 1404 moves the case to a court deemed more convenient or appropriate. It is not a dismissal or a merits ruling. All claims, defenses, and evidence travel with the case. The litigation over US11285129B2 continues in the District of Delaware — a leading forum for pharmaceutical patent disputes — with no prejudice to either party's substantive position.
No merits adjudicationDistrict of Delaware: a high-stakes pharmaceutical patent forum
Delaware is one of the most active and experienced forums for ANDA and Hatch-Waxman pharmaceutical patent litigation. Transfer there typically means exposure to well-developed local patent rules, experienced patent judges, and a concentrated docket of comparable cases. For Vanda, the venue shift may affect litigation strategy, local counsel requirements, and scheduling norms.
Transferred to D. Del.Infringement claims to be litigated from scratch in Delaware
Following transfer, the District of Delaware court will manage all subsequent proceedings: claim construction, fact and expert discovery, summary judgment, and trial if the case is not resolved earlier. The transfer order itself carries no implication about the strength or weakness of Vanda's infringement claims or Teva's defenses. Both parties retain their full legal positions.
Proceedings restart in D. Del.Venue selection remains a critical early battleground in pharma patent suits
This case illustrates that defendants in pharmaceutical patent actions can and do contest venue aggressively at the outset — and can succeed quickly. For patent holders asserting rights in New Jersey, a § 1404 transfer motion filed promptly can redirect proceedings to Delaware before any claim construction or discovery investment. Early venue analysis should be a standard element of litigation planning in this sector.
Early venue strategy mattersFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vanda Pharmaceuticals, Inc. | Company | Specialty biopharma company — holder of US11285129B2 for circadian rhythm disorder treatmentSearch in Eureka ↗ |
| Defendant | Teva Pharmaceutical Industries, Ltd. | Company | Global generic and specialty pharmaceutical manufacturer; Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Justin Taylor Quinn | Attorney | Counsel for Vanda Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Vanda Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | Christine Intromasso Gannon | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Lauren Ruth Malakoff | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant law firm | Walsh Pizzi O'Reilly Falanga LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the circadian rhythm therapeutics patent space
Forward-looking patent and innovation intelligence for teams tracking Vanda Pharmaceuticals, Teva, and the circadian rhythm disorder treatment landscape.
Vanda's circadian rhythm patent filing activity
Vanda Pharmaceuticals has built a focused patent estate around circadian biology and sleep-wake disorder therapeutics. Tracking Vanda's continuation filings, divisional applications, and new claim strategies around US11285129B2 can reveal how broadly the company intends to fence its exclusivity in this category and where claim scope may be expanding or narrowing.
Vanda portfolio depthFiling trends in circadian rhythm disorder treatment patents
The circadian rhythm therapeutics space is seeing growing patent activity from both branded pharmaceutical companies and academic institutions. Monitoring filing trends around chronobiotic agents, melatonin receptor agonists, and light-therapy adjuncts can identify where competitors are directing R&D and where patent density may create freedom-to-operate challenges for new entrants.
Circadian filing trendsTeva's patent and R&D position in sleep disorder generics
Teva's decision to contest venue aggressively rather than seek early settlement suggests confidence in its legal position. Analysing Teva's own patent filings in the sleep and circadian disorder space, alongside its ANDA history, can reveal its generic pipeline strategy and whether it holds defensive IP that may be relevant to the Delaware proceedings.
Teva generic pipelineAdjacent innovation opportunities near US11285129B2
Claim mapping around US11285129B2 may reveal adjacent white space in circadian disorder therapeutics — including novel dosing regimens, delivery mechanisms, or combination therapies not squarely covered by Vanda's current claims. R&D teams can use this analysis to design around the patent or identify patentable differentiation for next-generation products in the sleep-wake disorder category.
Design-around opportunitiesSimilar pharmaceutical patent transfer and infringement cases in federal courts
Explore related Hatch-Waxman infringement actions in the District of New Jersey and District of Delaware involving pharmaceutical patent enforcement and § 1404 venue transfers.
What this case signals for the pharma patent IP landscape
A 45-day transfer underscores how critical venue selection and early procedural strategy are in pharmaceutical patent enforcement.
Defendants can neutralise home-court advantage fast with § 1404
Teva and the Apotex entities secured transfer to Delaware within 45 days of the New Jersey filing — before any discovery or claim construction. Patent holders asserting pharma patents should stress-test venue selection before filing and model the § 1404 risk in jurisdictions where defendants have strong transfer arguments.
Delaware remains the gravitational centre for Hatch-Waxman disputes
The court's willingness to transfer to Delaware reinforces that district's dominance as the preferred forum for pharmaceutical patent litigation. Companies monitoring Vanda's circadian rhythm portfolio should track how this litigation unfolds under Delaware's well-developed patent case management practices.
Vanda v Teva — key questions answered
The District of New Jersey transferred this patent infringement action to the District of Delaware on February 10, 2023, just 45 days after filing. The court granted defendants' cross-motions under 28 U.S.C. § 1404. No merits ruling on infringement or validity of US11285129B2 was issued in New Jersey.
Vanda asserted US11285129B2 (application no. US17/368160), a patent covering treatment of circadian rhythm disorders. The product category at issue is the therapeutic treatment of circadian rhythm disorders.
The court granted defendants' cross-motions to transfer pursuant to 28 U.S.C. § 1404, which permits transfer to a more convenient or appropriate forum. The court considered full briefing, declarations, and exhibits before ordering transfer. The specific § 1404 factors that drove the decision are set out in the accompanying opinion referenced in the transfer order.
No. A § 1404 transfer is a purely procedural venue ruling — it does not adjudicate the merits of infringement or validity. Vanda's claims under US11285129B2 and Teva's defenses continue in the District of Delaware with no legal prejudice to either party's substantive position.
Yes. A companion action, Case No. 22-7529, was filed simultaneously in New Jersey against Apotex Inc. and Apotex Corp. over the same patent. Both cases were transferred to the District of Delaware by the same February 10, 2023 order granting the cross-motions to transfer.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.